KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Goodwill & Intangibles (2016 - 2025)

Vertex Pharmaceuticals has reported Goodwill & Intangibles over the past 17 years, most recently at $1.5 billion for Q4 2025.

  • Quarterly results put Goodwill & Intangibles at $1.5 billion for Q4 2025, down 20.86% from a year ago — trailing twelve months through Dec 2025 was $1.5 billion (down 20.86% YoY), and the annual figure for FY2025 was $1.5 billion, down 20.86%.
  • Goodwill & Intangibles for Q4 2025 was $1.5 billion at Vertex Pharmaceuticals, roughly flat from $1.5 billion in the prior quarter.
  • Over the last five years, Goodwill & Intangibles for VRTX hit a ceiling of $1.9 billion in Q4 2023 and a floor of $1.4 billion in Q2 2022.
  • Median Goodwill & Intangibles over the past 5 years was $1.6 billion (2022), compared with a mean of $1.6 billion.
  • Biggest five-year swings in Goodwill & Intangibles: increased 21.77% in 2023 and later dropped 20.93% in 2025.
  • Vertex Pharmaceuticals' Goodwill & Intangibles stood at $1.4 billion in 2021, then grew by 20.64% to $1.7 billion in 2022, then increased by 13.97% to $1.9 billion in 2023, then fell by 0.1% to $1.9 billion in 2024, then dropped by 20.86% to $1.5 billion in 2025.
  • The last three reported values for Goodwill & Intangibles were $1.5 billion (Q4 2025), $1.5 billion (Q3 2025), and $1.5 billion (Q2 2025) per Business Quant data.